India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

U.S. Representative Andy Barr (R-KY) introduced H.R. 478, the “Promoting New Bank Formation Act,” which was referred to the ...

Portuguese state-owned bank Caixa Geral de Depositos SA is analyzing the possible acquisition of Novo Banco SA, a smaller ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...